Article Excerpt: Nearly 175 people representing the digital health and pharmaceutical industries, health care systems, clinicians, scientists, investors, Dartmouth students and faculty, and government officials representing the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) gathered on Dartmouth’s campus November 2 for daylong discussions centered on digital therapeutics. Hosted by Geisel School of Medicine’s Center for Technology and Behavioral Health (CTBH) and Dartmouth’s Magnuson Center for Entrepreneurship, the program provided an overview of the science and clinical practice of digital therapeutics, the current and anticipated paths to their global deployment, and a vision for the future. This is the first time these groups have come together in conversations hosted by an academic institution about the digital health landscape and may well be viewed as a seminal moment in the rapidly developing field.
Full Article: https://tinyurl.com/2fnhbyxa
Article Source: Dartmouth Geisel School of Medicine News